Use of anti-LFA-1 monoclonal antibody carried out for producing a drug capable of preventing rejection of organ transplantation, and drug obtained by the production

摘要

Mean survival times of a functional transplant of solid organs in a patient are increased by administering to the patient an initial dosing of a therapeutically effective amounts of a monoclonal antibody directed against the human LFA-1 molecule in the two hours after grafting and then administering daily dosing during a period of approximately nine days.